Stay updated on Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page’s footer revision/version has been updated from **v3.5.0** to **v3.5.3**, reflecting a site release update without altering the study details.SummaryDifference0.0%

- Check36 days agoChange DetectedReplaced the study site entry Padua, Veneto, Italy, 35128 with Padova, Veneto, Italy, 35128. The city name is updated to the local spelling in the locations list.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page adds a reference to Hepatocellular carcinoma and includes the Genetic and Rare Diseases Information Center as a resource. It also updates the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check65 days agoChange DetectedThe page revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check87 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check95 days agoChange DetectedThe page revision was updated from v3.4.0 to v3.4.1; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial page.